Castle Creek Pharmaceutical Holdings, Inc. (“CCP Holdings”), a privately held company focused on developing medicine for important rare genetic disorders, today announced it has successfully completed the acquisition of Fibrocell Science, Inc., a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases.
| EXTON, Pa., Dec. 16, 2019 /PRNewswire/ -- Castle Creek Pharmaceuticals Holdings, Inc. (“CCP Holdings”), a privately held company focused on developing medicine for important rare genetic disorders, today announced it has successfully completed the acquisition of Fibrocell Science, Inc., a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases. The combined organization is committed to advancing late-stage development programs in important rare genetic diseases such as epidermolysis bullosa (EB) and plans to target additional rare conditions with the gene therapy platform. Both Castle Creek and Fibrocell have advanced investigational therapies for the treatment of EB into late-stage clinical research. EB is a rare genetic condition that leads to extremely fragile skin resulting in mild to severe blistering, skin erosion and peeling of the epidermis layers in response to minor injury. There are currently no treatment options approved by the U.S. Food & Drug Administration (FDA) for any form of EB. “Our organizations have a shared commitment to delivering new treatment options to underserved communities such as EB patients and their families who have no approved therapies,” said Greg Wujek, chief executive officer of Castle Creek. “The addition of this late stage gene therapy will allow us to be the leader in rare genetic dermatology and additional genetic diseases as well.” Prior to the acquisition, Fibrocell initiated a pivotal Phase 3 clinical trial evaluating a gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The FDA has granted Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, Rare Pediatric Disease and Fast Track designations to FCX-007. Castle Creek has also continued Phase 2b clinical research evaluating a diacerein topical ointment, CCP-020, for epidermolysis bullosa simplex (EBS) and other forms of EB. The FDA has designated the CCP-020 program for Fast Track development in the treatment of EBS. Castle Creek is a portfolio company of Paragon Biosciences, which founded Castle Creek with the vision to deliver transformative therapies to patients with rare genetic dermatologic diseases. About Castle Creek Pharmaceutical Holdings, Inc. About Castle Creek Pharmaceuticals, LLC About Fibrocell About Paragon Biosciences Media Contacts: Karen Casey Jeff Winton
SOURCE Castle Creek Pharmaceuticals |
View original content:
